750,000 doses of influenza vaccine to be supplied to Southeast Asia and Latin America in the first half of the year. Expanded exports markets ensure year-round vaccine production, enhancing supply stability and cost efficiency. Company accelerates global market entry with in-house developed vaccines for influenza, varicella, shingles, and typhoid.
SEONGNAM, South Korea , March 12, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has begun shipping its self-developed influenza vaccine, SKYCellflu, from its vaccine manufacturing facility L HOUSE to Southern Hemisphere markets, including Southeast Asia and Latin America . A total of 750,000 doses will be supplied in the first half of the year. This shipment marks the company's second export of influenza vaccines for Southern Hemisphere use, following its initial export to Thailand last year.
Although Thailand is geographically located in the Northern Hemisphere, it follows both WHO's flu vaccination guidelines for the Northern and Southern Hemispheres due to its north-south span. The WHO forecasts circulating influenza strains and recommends vaccines twice a year - once for the Northern Hemisphere and once for the Southern Hemisphere. By increasing exports to the Southern Hemisphere, SK bioscience can maintain year-round vaccine production, improving supply stability and cost efficiency in the global m.